Developer docs
API playgroundTry for free, no card

Search company profiles

Plexium

Full company profile

uuid00008xk

Namestring
Plexium
Legal namestring
Plexium, Inc.
Websiteurl
plexium.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Plexium, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California (Delaware-incorporated), founded in 2018, that develops targeted protein degradation (TPD) therapeutics for oncology. The company's pipeline focuses on small-molecule monovalent direct degraders and molecular glue degraders that hijack the cellular ubiquitin-proteasome system to eliminate disease-driving proteins, including targets historically considered undruggable. Its lead clinical programs include PLX-61639, an oral SMARCA2-selective direct degrader for SMARCA4-mutated solid tumors, and PLX-4545, an oral IKZF2 molecular glue degrader for immune-checkpoint combination therapy; a third asset, PLX-66140, is an oral CDK2 molecular glue degrader in earlier development for ER+/Her2- breast cancer and CCNE1-amplified tumors.

The company's discovery engine is the DELTA Discovery™ platform, which integrates proprietary degrader chemistry design, ultra-high throughput cell-based screening using miniaturized Picowell devices, AI-guided structure-based drug design, and degrader-centric CRISPR knockout screens that have yielded multiple internally identified novel E3 ligases and a 1+ million-member on-bead Cereblon binder library. Plexium's revenue model is pre-commercial: it monetizes the platform through upfront fees, R&D funding, milestones, and potential royalties under multi-year pharmaceutical collaborations — most notably a multi-year research collaboration and license agreement with Amgen signed in February 2022 alongside a $102M financing round — supplemented by equity capital from institutional venture investors. Patients access the company's investigational medicines exclusively via participation in registered clinical trials (e.g., NCT07284186, ANZCTR-12623001265662); no products are commercially approved or priced.

Short descriptiontext

Plexium is a privately held, clinical-stage biopharmaceutical company developing orally bioavailable monovalent and molecular glue targeted protein degraders for oncology, with lead programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) in Phase 1 trials, powered by its proprietary DELTA Discovery™ platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, protein degrader therapeutics, monovalent direct degraders, molecular glue degraders, oncology drug discovery
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Targeted Protein Degradation Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research Collaboration and Licensing Revenue
TypeLicensing Royalties
Description

Multi-year research collaboration and license deals with pharmaceutical partners, including milestone payments, upfront fees, and potential royalties on commercialized products. Plexium announced a collaboration and license deal with Amgen to develop targeted protein degradation therapeutics.

biospace.com
2Equity Financing
TypeSubscription Recurring
Description

Company has raised significant equity capital through funding rounds ($102M in 2022) and SEC Form D filings for exempt securities offerings ($60M+ in 2025) to fund R&D and clinical development operations.

sec.gov
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Plexium is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics, including monovalent direct degraders and molecular glue degraders. Its pipeline includes clinical-stage programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) and earlier-stage PLX-66140 (CDK2), all powered by its proprietary DELTA Discovery platform for oncology indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SMARCA4 loss of function mutations occur in 5-7% of all human cancers
+2 more records
Product overview1 text field

Plexium is a premier next-generation targeted protein degradation (TPD) company that develops monovalent targeted protein degrader therapeutics. The company's offering consists of the DELTA Discovery™ Platform, which powers drug discovery through proprietary ultra-high throughput cell-based screening, combined with two degrader modalities: Monovalent Direct Degraders and Molecular Glue Degraders. The pipeline includes clinical-stage programs PLX-61639 (SMARCA2 direct degrader) and PLX-4545 (IKZF2 molecular glue degrader), along with PLX-66140 (CDK2 molecular glue) in earlier development, all focused on addressing high unmet medical needs in oncology.

Product and service4 records
1DELTA Discovery Platform
CategoryDrug Discovery Platform
Description

A proprietary drug discovery platform integrating degrader chemistry design principles with ultra-high throughput cell-based screening to identify drug-like, cell-permeable monovalent degrader drug candidates for internal pipeline and partnership programs.

2PLX-61639 (SMARCA2 Degrader)
CategoryClinical-Stage Therapeutic Candidate
Description

An oral SMARCA2-selective direct degrader in Phase 1 clinical development for the treatment of patients with SMARCA4-mutated locally advanced or metastatic solid tumors.

3PLX-4545 (IKZF2 Molecular Glue Degrader)
CategoryClinical-Stage Therapeutic Candidate
Description

An oral IKZF2-selective molecular glue degrader in Phase 1 clinical development as monotherapy and in combination to improve clinical responses to immune checkpoint inhibitors across multiple solid tumor types.

4PLX-66140 (CDK2 Molecular Glue Degrader)
CategoryPreclinical Therapeutic Candidate
Description

A potent, highly selective and orally bioavailable CDK2 molecular glue degrader in preclinical/early development for ER+, Her2- breast cancer and CCNE1-amplified tumor types.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-02-23
Description

Multi-year research collaboration and license deal with Amgen to develop targeted protein degradation therapeutics. Plexium received $102 million in funding alongside this collaboration, combining Amgen's pharmaceutical capabilities with Plexium's targeted protein degradation expertise.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage leader in targeted protein degradation using PROTAC technology, with multiple oncology programs in Phase 1-3 trials. Directly comparable to Plexium as a TPD platform company developing small-molecule degraders for previously 'undruggable' oncology targets.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing targeted protein degraders with a focus on immunology and oncology. Closely comparable to Plexium on TPD modality, platform-driven pipeline expansion, and clinical-stage execution.

TypeDirect peer
Description

Clinical-stage company developing targeted protein modulators using both degraders and stabilizers, with significant focus on molecular glue degraders using Cereblon-based chemistry — directly analogous to Plexium's glue degrader approach.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing small-molecule degraders using both monomeric (degronimids) and dimeric (PROTAC) approaches for oncology targets. Closely comparable to Plexium on TPD modality and clinical-stage pipeline.

TypeDirect peer
Description

Clinical-stage biotech developing molecular glue degraders, with emphasis on leveraging cereblon and other E3 ligases for oncology and immunology indications. Directly comparable on molecular glue degrader modality and undruggable target focus.

TypeDirect peer
Description

Clinical-stage oncology company focused on chromatin biology and protein degradation. Comparable to Plexium in using platform-driven discovery for previously undruggable oncology targets, though Foghorn emphasizes chromatin regulatory proteins.

TypeEmerging player
Description

Emerging European-based targeted protein degradation company developing next-generation TPDs with novel mechanisms beyond traditional PROTACs. Comparable as an emerging TPD platform competitor with novel E3 ligase ambitions.

TypeEmerging player
Description

Clinical-stage company developing targeted protein degraders and modulators using small molecules, including PHM (pharmacological hybrid modulators). Emerging competitor in the TPD space with overlap to Plexium's monovalent degrader approach.

TypeEmerging player
Description

Clinical-stage oncology company developing targeted protein degraders, including SP-3164 (formerly Avadomide) and preclinical programs. Smaller-scale comparable to Plexium as a clinical TPD developer focused on hematologic and solid tumor indications.

TypeBroad incumbent
Description

Large-cap biopharmaceutical company with broad oncology and protein degradation capabilities, and Plexium's strategic collaboration and license partner. Included as a broad incumbent that operates in the same oncology space and validates the platform via partnership.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Plexium

Targeted Protein Degradation Therapeuticsplexium.com

Plexium is a privately held, clinical-stage biopharmaceutical company developing orally bioavailable monovalent and molecular glue targeted protein degraders for oncology, with lead programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) in Phase 1 trials, powered by its proprietary DELTA Discovery™ platform.

What Plexium does

Plexium, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California (Delaware-incorporated), founded in 2018, that develops targeted protein degradation (TPD) therapeutics for oncology. The company's pipeline focuses on small-molecule monovalent direct degraders and molecular glue degraders that hijack the cellular ubiquitin-proteasome system to eliminate disease-driving proteins, including targets historically considered undruggable. Its lead clinical programs include PLX-61639, an oral SMARCA2-selective direct degrader for SMARCA4-mutated solid tumors, and PLX-4545, an oral IKZF2 molecular glue degrader for immune-checkpoint combination therapy; a third asset, PLX-66140, is an oral CDK2 molecular glue degrader in earlier development for ER+/Her2- breast cancer and CCNE1-amplified tumors.

The company's discovery engine is the DELTA Discovery™ platform, which integrates proprietary degrader chemistry design, ultra-high throughput cell-based screening using miniaturized Picowell devices, AI-guided structure-based drug design, and degrader-centric CRISPR knockout screens that have yielded multiple internally identified novel E3 ligases and a 1+ million-member on-bead Cereblon binder library. Plexium's revenue model is pre-commercial: it monetizes the platform through upfront fees, R&D funding, milestones, and potential royalties under multi-year pharmaceutical collaborations — most notably a multi-year research collaboration and license agreement with Amgen signed in February 2022 alongside a $102M financing round — supplemented by equity capital from institutional venture investors. Patients access the company's investigational medicines exclusively via participation in registered clinical trials (e.g., NCT07284186, ANZCTR-12623001265662); no products are commercially approved or priced.

Plexium firmographics

Firmographics
Name
Plexium
Legal name
Plexium, Inc.
Website
https://plexium.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Plexium is a privately held, clinical-stage biopharmaceutical company developing orally bioavailable monovalent and molecular glue targeted protein degraders for oncology, with lead programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) in Phase 1 trials, powered by its proprietary DELTA Discovery™ platform.
Ownership category
akta.pro rank

Plexium industry classification

Industry
Product category
Targeted Protein Degradation Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Protein degrader therapeutics
  • Monovalent direct degraders
  • Molecular glue degraders
  • Oncology drug discovery

Where Plexium is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Plexium business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Research Collaboration and Licensing Revenue: Multi-year research collaboration and license deals with pharmaceutical partners, including milestone payments, upfront fees, and potential royalties on commercialized products. Plexium announced a collaboration and license deal with Amgen to develop targeted protein degradation therapeutics.
  2. Equity Financing: Company has raised significant equity capital through funding rounds ($102M in 2022) and SEC Form D filings for exempt securities offerings ($60M+ in 2025) to fund R&D and clinical development operations.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Plexium product offering

Product offering

Core offering

Plexium is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics, including monovalent direct degraders and molecular glue degraders. Its pipeline includes clinical-stage programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) and earlier-stage PLX-66140 (CDK2), all powered by its proprietary DELTA Discovery platform for oncology indications.

Product overview

Plexium is a premier next-generation targeted protein degradation (TPD) company that develops monovalent targeted protein degrader therapeutics. The company's offering consists of the DELTA Discovery™ Platform, which powers drug discovery through proprietary ultra-high throughput cell-based screening, combined with two degrader modalities: Monovalent Direct Degraders and Molecular Glue Degraders. The pipeline includes clinical-stage programs PLX-61639 (SMARCA2 direct degrader) and PLX-4545 (IKZF2 molecular glue degrader), along with PLX-66140 (CDK2 molecular glue) in earlier development, all focused on addressing high unmet medical needs in oncology.

Differentiator

Problem solved

Functional benefit

Products and services

  • DELTA Discovery Platform A proprietary drug discovery platform integrating degrader chemistry design principles with ultra-high throughput cell-based screening to identify drug-like, cell-permeable monovalent degrader drug candidates for internal pipeline and partnership programs.
  • PLX-61639 (SMARCA2 Degrader) An oral SMARCA2-selective direct degrader in Phase 1 clinical development for the treatment of patients with SMARCA4-mutated locally advanced or metastatic solid tumors.
  • PLX-4545 (IKZF2 Molecular Glue Degrader) An oral IKZF2-selective molecular glue degrader in Phase 1 clinical development as monotherapy and in combination to improve clinical responses to immune checkpoint inhibitors across multiple solid tumor types.
  • PLX-66140 (CDK2 Molecular Glue Degrader) A potent, highly selective and orally bioavailable CDK2 molecular glue degrader in preclinical/early development for ER+, Her2- breast cancer and CCNE1-amplified tumor types.

Quantifiable outcome

  • SMARCA4 loss of function mutations occur in 5-7% of all human cancers
  • +2 more outcomes

Companies that use Plexium

Customer profile

Segments1 record

Ideal customer profiles2 records

Plexium technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Plexium partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AmgencoreStrategic or Co-development Partner · 23 February 2022Multi-year research collaboration and license deal with Amgen to develop targeted protein degradation therapeutics. Plexium received $102 million in funding alongside this collaboration, combining Amgen's pharmaceutical capabilities with Plexium's targeted protein degradation expertise.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Plexium competitors and assessment

Company assessment

Direct peers

  • Arvinas: Clinical-stage leader in targeted protein degradation using PROTAC technology, with multiple oncology programs in Phase 1-3 trials. Directly comparable to Plexium as a TPD platform company developing small-molecule degraders for previously 'undruggable' oncology targets.
  • Kymera Therapeutics: Clinical-stage biopharmaceutical company developing targeted protein degraders with a focus on immunology and oncology. Closely comparable to Plexium on TPD modality, platform-driven pipeline expansion, and clinical-stage execution.
  • Nurix Therapeutics: Clinical-stage company developing targeted protein modulators using both degraders and stabilizers, with significant focus on molecular glue degraders using Cereblon-based chemistry — directly analogous to Plexium's glue degrader approach.
  • C4 Therapeutics: Clinical-stage biopharmaceutical company developing small-molecule degraders using both monomeric (degronimids) and dimeric (PROTAC) approaches for oncology targets. Closely comparable to Plexium on TPD modality and clinical-stage pipeline.
  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders, with emphasis on leveraging cereblon and other E3 ligases for oncology and immunology indications. Directly comparable on molecular glue degrader modality and undruggable target focus.
  • Foghorn Therapeutics: Clinical-stage oncology company focused on chromatin biology and protein degradation. Comparable to Plexium in using platform-driven discovery for previously undruggable oncology targets, though Foghorn emphasizes chromatin regulatory proteins.

Emerging players

  • Amphista Therapeutics: Emerging European-based targeted protein degradation company developing next-generation TPDs with novel mechanisms beyond traditional PROTACs. Comparable as an emerging TPD platform competitor with novel E3 ligase ambitions.
  • BioTheryX: Clinical-stage company developing targeted protein degraders and modulators using small molecules, including PHM (pharmacological hybrid modulators). Emerging competitor in the TPD space with overlap to Plexium's monovalent degrader approach.
  • Salarius Pharmaceuticals: Clinical-stage oncology company developing targeted protein degraders, including SP-3164 (formerly Avadomide) and preclinical programs. Smaller-scale comparable to Plexium as a clinical TPD developer focused on hematologic and solid tumor indications.

Broad incumbents

  • Amgen: Large-cap biopharmaceutical company with broad oncology and protein degradation capabilities, and Plexium's strategic collaboration and license partner. Included as a broad incumbent that operates in the same oncology space and validates the platform via partnership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Plexium social profiles

Digital presence

Plexium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Plexium leadership team

Management profile

Number of profiles

Profiles13 records

Plexium funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Plexium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plexium

What does Plexium do?

Plexium is a clinical-stage biopharmaceutical company that discovers and develops targeted protein degradation (TPD) therapeutics, including monovalent direct degraders and molecular glue degraders. Its pipeline includes clinical-stage programs PLX-61639 (SMARCA2) and PLX-4545 (IKZF2) and earlier-stage PLX-66140 (CDK2), all powered by its proprietary DELTA Discovery platform for oncology indications.

Is Plexium a public or private company?

Plexium is a private company. It is classified as venture growth investor backed and is currently operating.

When was Plexium founded?

Plexium was founded in 2018. It employs 11 to 50 people.

Where is Plexium based?

Plexium is headquartered in San Diego, United States, in the North America region.

How does Plexium make money?

Two revenue lines are on record. Research Collaboration and Licensing Revenue is the primary driver. The others are equity Financing.

Who are Plexium's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, Monte Rosa Therapeutics and Foghorn Therapeutics. Emerging players are Amphista Therapeutics, BioTheryX and Salarius Pharmaceuticals. Amgen is listed as a broad incumbent.

Does Plexium have an API?

No public API is recorded for Plexium.

What industry is Plexium in?

Plexium's product category is Targeted Protein Degradation Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldPLX-61639 shows efficacy in SMARCA4-mutant tumorsResearchers from Plexium Inc. presented preclinical efficacy data for PLX-61639, a SMARCA2-selective degrader, in SMARCA4-mutant tumor models. The data was presented at the American Association for Cancer Research meeting.FierceBiotechMonths after layoffs, AbbVie-partnered protein degrader specialist Plexium raises $60MPlexium raised $60.1 million in a financing round, three years after its 2022 breakout year. The biotech's phase 1 trial of PLX-4545 showed an acceptable safety profile and reprogrammed regulatory T cells, warranting further investigation. The company also laid off employees to align resources with its pipeline.SecSEC FORM DPlexium, Inc., a Delaware-based biotechnology company headquartered in San Diego, California, filed a Form D notice with the SEC on August 25, 2025, to report an exempt offering of equity securities under Rule 506(c). The company has completed the offering, having sold the full amount of $60,115,703 to 20 investors, with no minimum investment required and no sales commissions or finder's fees paid.FierceBiotechPlexium cuts staff, realigns resources to support protein degrader pipelinePlexium laid off staff to realign resources for its preclinical protein degrader pipeline. The company has one phase 1 asset, PLX-4545, and declined to disclose the number of affected employees. Novartis is running a phase 1 trial of its own IKZF2 degrader.PR NewswirePLEXIUM STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENT OF DANIEL SIPES AS SENIOR VICE PRESIDENT, HEAD OF TECHNOLOGYPlexium, Inc., a next-generation targeted protein degradation (TPD) company, announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology, effective immediately. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery, including high throughput screening and novel assay development, having previously held senior roles at Strateos and the Genomics Institute of the Novartis Research Foundation. Plexium noted Sipes's appointment will strengthen its proprietary TPD drug discovery platform, which powers strategic collaborations with Amgen and AbbVie in developing novel protein degraders for cancer, neurodegeneration, and other diseases.PR NewswirePLEXIUM APPOINTS BRIAN WONG, M.D., PH.D., TO ITS BOARD OF DIRECTORSPlexium, Inc., a San Diego-based biotechnology company specializing in targeted protein degradation, announced the appointment of Brian Wong, M.D., Ph.D. to its Board of Directors. Dr. Wong brings more than two decades of experience in biotechnology and large pharmaceutical sectors, having advanced over 20 programs from discovery through clinical development and approval. He currently serves as President and CEO of RAPT Therapeutics and previously held senior leadership roles at Five Prime Therapeutics, Roche, and Rigel Pharmaceuticals.socaltech.comPlexium Names New Board MemberPlexium, a San Diego-based targeted protein degradation company, appointed Brian Wong, president and CEO of RAPT Therapeutics, to its board. Wong previously held roles at Five Prime Therapeutics and Roche. The company is venture-backed by Lux Capital, Pivotal BioVentures, and others.PR NewswirePlexium Appoints Stephen Mullennix as Chief Financial OfficerPlexium, Inc. announced the appointment of Stephen Mullennix as Chief Financial Officer, bringing over 20 years of financial and operational expertise in biotechnology and private equity to the company. Mullennix joins from ProSciento, Inc., where he served as CFO, and previously held CFO and COO roles at UroGen Pharma, Ltd. and SolarReserve, LLC, having been directly involved in $3.3 billion of public, private, equity, debt and M&A transactions.BioSpaceAbbVie Unites with Plexium to Leverage Protein Degraders Against Neurological DiseasesAbbVie has entered an exclusive strategic partnership with Plexium to develop and commercialize Targeted Protein Degradation (TPD) therapeutics for neurological conditions. Under the agreement, AbbVie paid an undisclosed upfront fee and will have options to advance Plexium's preclinical research into further development and global commercialization. Plexium retains rights to participate in product development and receive tiered royalties on any resulting therapies.Endpoints NewsMore mol­e­c­u­lar glue: Plex­i­um pens Ab­b­Vie pact months af­ter Am­gen dealPlexium, a San Diego-based biotech, signed a deal with AbbVie months after its deal with Amgen. The company, led by CEO Percival Barretto-Ko, is pursuing additional partnerships with major pharma firms.